Southport Capital Management’s AbbVie ABBV Stock Holding History

Southport Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-500	Closed	-$48K	–	190
2017 Q4	$48K	Buy	+500	New	+$47.1K	0.02%	195

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Southport Capital Management's ABBV Position: Q1 2022 in Review

Southport Capital Management reduced its AbbVie (ABBV) stake by 53% in Q1 2022, selling an estimated $220K and leaving 1,320 shares worth $214K. The position accounts for 0.08% of the portfolio, ranked #207.

Southport Capital Management first reported a position in ABBV in Q2 2013 and has held it in 36 quarters since. The position peaked at $1.73M in Q4 2017. 3,053 funds tracked by Wall St. Rank hold ABBV as of Q1 2022.

Southport Capital Management held 1,320 shares of AbbVie worth $214K as of Q1 2022.
Southport Capital Management sold 1,513 AbbVie shares in Q1 2022, an estimated $220K.
AbbVie made up 0.08% of Southport Capital Management's portfolio in Q1 2022, its #207 holding.
Southport Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 36 quarters since.
Southport Capital Management's AbbVie position peaked at $1.73M in Q4 2017.
3,053 funds tracked by Wall St. Rank held AbbVie as of Q1 2022.

Based on Southport Capital Management's 13F filing for Q1 2022, filed 25 Apr 2022.